NICE, France, Sept. 17, 2015 /PRNewswire/ — Okuvision GmbH, the leading developer of transcorneal electrical stimulation (TES) therapy for early and intermediate stage retinitis pigmentosa (RP) patients, announced today that post-market clinical data of the Company’s CE marked OkuStim® treatment will be presented at the European Society of Retina Specialists (EURETINA) Congress 2015. Key findings from the TESOLA and EST II studies will be presented by Dr.Lubka Naycheva, specialist and head of the outpatient clinic at the University Eye Hospital Frankfurt, Germany at the retina industry’s leading conference, now in its 15th year, taking place 17-20 September in Nice, France.
Dr. Naycheva’s presentation titled “Transcorneal Electrical Stimulation Treatment for Patients with Retinitis Pigmentosa – Summary of Results from the TESOLA Study – a Multicentric Observational Study” highlights the results of 105 patients who were treated with OkuStim for 30 minutes weekly over a period of six months. The majority of patients reported satisfaction with the therapy. Further information on the study’s findings will be presented as a free paper scheduled for Thursday, 17 September at 02:40 PM, Room Calliope, Acropolis as well as a poster presentation number 7679 17 – 20 September 2015 in Acropolis, Nice.
For more info: